dc.contributor
Institut Català de la Salut
dc.contributor
[Tejada S] Grup de Recerca Clínica/Innovació en Pneumònia i Sèpsia (CRIPS), Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Centro de Investigación Biomédica En Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. [Ramírez-Estrada S] Intensive Care Department, Clínica Corachán, Barcelona, Spain. [Forero CG] School of Medicine, Universitat Internacional de Catalunya, Barcelona, Spain. [Gallego M] Centro de Investigación Biomédica En Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Respiratory Department, Parc Taulí University Hospital, Barcelona, Spain. [Soriano JB] Centro de Investigación Biomédica En Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Hospital Universitario La Princesa, Universidad Autónoma de Madrid, Madrid, Spain. [Cardinal-Fernández PA] Intensive Care Unit, HM Group, Madrid, Spain. [Ehrmann S] CHRU Tours, Médecine Intensive Réanimation, CIC INSERM 1415, CRICS-TriggerSEP F-CRIN Research Network, Tours, France. Centre d’étude des Pathologies Respiratoires, INSERM U1100, Université de Tours, Tours, France. [Rello J] Grup de Recerca Clínica/Innovació en Pneumònia i Sèpsia (CRIPS), Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Clinical Research in the ICU, CHU Nimes, Universite de Nimes-Montpellier, Nimes, France. Medicine Department, Universitat Internacional de Catalunya (UIC), Sant Cugat, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Ramírez-Estrada, Sergio
dc.contributor.author
Forero, Carlos G.
dc.contributor.author
Gallego, Miguel
dc.contributor.author
Cardinal-Fernandez, P
dc.contributor.author
Ehrmann, Stephan
dc.contributor.author
Rello Condomines, Jordi
dc.contributor.author
Soriano, Joan B
dc.contributor.author
Tejada Magraner, Sofia
dc.date.accessioned
2025-10-24T08:50:51Z
dc.date.available
2025-10-24T08:50:51Z
dc.date.issued
2022-07-20T11:39:12Z
dc.date.issued
2022-07-20T11:39:12Z
dc.date.issued
2022-02-19
dc.identifier
Tejada S, Ramírez-Estrada S, Forero CG, Gallego M, Soriano JB, Cardinal-Fernández PA, et al. Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis. Antibiotics. 2022 Feb 19;11(2):275.
dc.identifier
https://hdl.handle.net/11351/7886
dc.identifier
10.3390/antibiotics11020275
dc.identifier
000767149500001
dc.identifier.uri
http://hdl.handle.net/11351/7886
dc.description.abstract
Bronchiectasis; Dry powder inhaled; Inhaled antibiotics
dc.description.abstract
Bronquiectasias; Polvo seco inhalado; Antibióticos inhalados
dc.description.abstract
Bronquiectasies; Pols seca inhalada; Antibiòtics inhalats
dc.description.abstract
It remains unknown whether the type of aerosol generating device is affecting efficacy and safety among non-cystic fibrosis bronchiectasis (NCFB) adults. The proposal of this network meta-analysis (NMA) is to evaluate effectiveness and safety of inhaled antibiotics administered via dry powder inhaler (DPI) and via nebulizers (SVN) among adult patients with NCFB. Inclusion criteria were randomized-controlled trials, adults (≥18 years) with NCFB, and inhaled antibiotics administered via DPI as intervention. Search strategy was performed in PubMed, Web of Science, and Cochrane Library from 2000 to 2019. Sixteen trials (2870 patients) were included. Three trials (all ciprofloxacin) used DPIs and thirteen used SVN (three ciprofloxacin). Both DPI and SVN devices achieved similar safety outcomes (adverse events, antibiotic discontinuation, severe adverse events, and bronchospasm). Administration of ciprofloxacin via DPI significantly improved time to first exacerbation (87 days, 95% CI 34.3–139.7) and quality of life (MD −7.52; 95% CI −13.06 to −1.98) when compared with via SVN. No other significant differences were documented in clinical efficacy (at least one exacerbation, FEV1% predicted) and microbiologic response (bacterial eradication, emergence of new potential pathogens, and emergence of antimicrobial resistance) when comparing devices. Our NMA documented that time to first exacerbation and quality of life, were more favorable for DPIs. Decisions on the choice of devices should incorporate these findings plus other criteria, such as simplicity, costs or maintenance requirements.
dc.description.abstract
This work was funded by CIBERES, Instituto de Salud Carlos III, Madrid, Spain (Fondos FEDER) (CB06-06-036).
dc.format
application/pdf
dc.relation
Antibiotics;11(2)
dc.relation
https://doi.org/10.3390/antibiotics11020275
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Bronquièctasi - Tractament
dc.subject
Avaluació de resultats (Assistència sanitària)
dc.subject
Teràpia respiratòria
dc.subject
DISEASES::Respiratory Tract Diseases::Bronchial Diseases::Bronchiectasis
dc.subject
Other subheadings::Other subheadings::Other subheadings::/drug therapy
dc.subject
ENFERMEDADES::enfermedades respiratorias::enfermedades bronquiales::bronquiectasia
dc.subject
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
dc.title
Safety and Efficacy of Devices Delivering Inhaled Antibiotics among Adults with Non-Cystic Fibrosis Bronchiectasis: A Systematic Review and a Network Meta-Analysis
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion
